Andrew Cheng - Jan 2, 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President and CEO, Director
Signature
Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Jan 2, 2024
Transactions value $
$24,600
Form type
4
Date filed
1/3/2024, 05:00 PM
Previous filing
Dec 18, 2023
Next filing
Mar 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $24.6K +40K +7.26% $0.62 591K Jan 2, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -40K -61.98% $0.00 24.5K Jan 2, 2024 Common Stock 40K $0.62 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are vested and currently exercisable.